Compare Ascendis Pharma A/S (ASND) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Wolfspeed Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Wolfspeed Inc trades at $34.13 (market cap $1.83B). The key difference: Ascendis Pharma A/S is far larger — about 9.7× Wolfspeed Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals.
| ASND | WOLF | |
|---|---|---|
Market Cap | $17.74B | $1.83B |
Sector | Health | Technology |
52-Week High | $277.18 | $73.68 |
52-Week Low | $163.32 | $1.19 |
Enterprise Value | $18.11B | $2.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
WOLF stock trades at $35.29, down 5.26% amid a bearish technical signal. The company faces financial challenges with negative gross and net income margins but shows strategic shifts toward AI data centers and defense markets. Recent news highlights a patent lawsuit against Navitas and a collaboration with GE Aerospace, indicating active business development. Technical indicators show mixed signals with key support at $34.
The outlook is cautious due to persistent losses and competitive pressures, though analyst sentiment is mixed with a slight buy bias. Key risks include cash burn and market volatility, while opportunities lie in strategic pivots to high-growth sectors. Investors should weigh the potential from new initiatives against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
